cbdMD (YCBD) Projected to Post Quarterly Earnings on Wednesday

cbdMD (NYSEAMERICAN:YCBD) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, August 19th. Analysts expect cbdMD to post earnings of ($0.03) per share and revenue of $5.6890 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:20 PM ET.

cbdMD (NYSEAMERICAN:YCBD) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). cbdMD had a negative net margin of 13.29% and a negative return on equity of 33.60%. The company had revenue of $5.64 million for the quarter, compared to analyst estimates of $5.29 million.

cbdMD Price Performance

Shares of NYSEAMERICAN YCBD opened at $0.58 on Wednesday. The stock has a 50 day moving average price of $0.65 and a 200 day moving average price of $0.75. cbdMD has a 52 week low of $0.47 and a 52 week high of $2.56.

Institutional Investors Weigh In On cbdMD

A hedge fund recently bought a new position in cbdMD stock. Jane Street Group LLC acquired a new stake in cbdMD, Inc. (NYSEAMERICAN:YCBD) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned about 0.49% of cbdMD at the end of the most recent quarter. Institutional investors and hedge funds own 7.18% of the company’s stock.

cbdMD Company Profile

cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.